GlobalData

J.D. Power-GlobalData U.S. Automotive Forecast for January 2024

Retrieved on: 
Friday, January 26, 2024
Fleet Management, Other Automotive, General Automotive, Automotive, EV, Electric Vehicles, SAAR, Insurance, MSRP, J.D. Power, GlobalData, Rare-earth element

January 2024 has 25 selling days, one more than January 2023.

Key Points: 
  • January 2024 has 25 selling days, one more than January 2023.
  • The seasonally adjusted annualized rate (SAAR) for total new-vehicle sales is expected to be 15.2 million units, flat from January 2023.
  • New-vehicle retail sales for January 2024 are expected to decrease when compared with January 2023.
  • Retail sales of new vehicles this month are expected to reach 862,400 units, a 1.8% decrease from January 2023.

GlobalData report highlights staggering economic costs for South Carolina of $7.4 billion due to obesity

Retrieved on: 
Wednesday, January 17, 2024
Labor, Fitness & Nutrition, Public Policy, Government, Healthcare Reform, Business, Professional Services, Health, State, Local, General Health, Welfare, Conditional sentence, Woman, Death, Medicaid, Weight loss, Culture, Medicare, Insurance, Federation, Eli Lilly and Company, Parity, Disease, DSM-IV codes, Workforce, Head, Overweight, GlobalData, Education, Pharmaceutical industry

GlobalData’s report, ‘ Obesity’s Impact on South Carolina's Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of South Carolina, as well as the impact on state tax revenue collections and costs.

Key Points: 
  • GlobalData’s report, ‘ Obesity’s Impact on South Carolina's Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of South Carolina, as well as the impact on state tax revenue collections and costs.
  • In South Carolina, approximately one-third of adults are classified as having obesity (35.0%), and another third have overweight (34.8%) in 2022.
  • Employers in South Carolina paid an extra $907 million in higher medical expenditures for health complications attributed to obesity and overweight.
  • The federal government also spent an estimated $1.7 billion more on Medicare and Medicaid for South Carolina residents.

GlobalData Names BostonGene Leading Innovator in AI-Driven Drug Repurposing

Retrieved on: 
Wednesday, January 3, 2024
Technology, Genetics, Software, Biotechnology, Health, Pharmaceutical, General Health, Artificial Intelligence, Oncology, GlobalData, Drug discovery, Medicine, Drug development, Research, Pharmaceutical industry, Artificial intelligence, Pharmaceutics, Machine learning, Patient, Therapy, Algorithm, Medical device

BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced that it has been named a leading innovator in AI drug repurposing in a recent report published in Pharmaceutical Technology, part of the GlobalData network.

Key Points: 
  • BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced that it has been named a leading innovator in AI drug repurposing in a recent report published in Pharmaceutical Technology, part of the GlobalData network.
  • The article, " Innovators in AI Drug Repurposing: Pioneering AI in the Pharmaceutical Industry ," showcases BostonGene at the forefront of innovation by leading in both geographical reach and application diversity.
  • GlobalData analyzed over 260 companies, spanning technology vendors, established pharmaceutical companies and up-and-coming start-ups engaged in the development and application of drug repurposing AI to determine their leadership ranking.
  • "We are honored to be recognized as innovators in AI drug repurposing," said Andrew Feinberg, President and CEO at BostonGene.

J.D. Power-GlobalData U.S. Automotive Forecast for December 2023

Retrieved on: 
Thursday, December 21, 2023
General Automotive, Fleet Management, EV, Electric Vehicles, Automotive, Original equipment manufacturer, GlobalData, SAAR, Growth, J.D. Power, Insurance, MSRP, OEM, Cryptocurrency

New-vehicle total sales for 2023 are projected to reach 15,466,000 units, a 13.2% increase from 2022 when adjusted for selling days.

Key Points: 
  • New-vehicle total sales for 2023 are projected to reach 15,466,000 units, a 13.2% increase from 2022 when adjusted for selling days.
  • New-vehicle retail sales for December 2023 are expected to increase when compared with December 2022.
  • New-vehicle retail sales in Q4 2023 are projected to reach 3,186,700 units, a 9.8% increase from Q4 2022 when adjusted for selling days.
  • New-vehicle retail sales for 2023 are projected to reach 12,645,600 units, an 8.4% increase from 2022 when adjusted for selling days.

Banco de la República de Colombia and ACI Worldwide Partner to Power Real-Time Payments in Colombia

Retrieved on: 
Wednesday, December 13, 2023
Payments, Finance, Banking, Professional Services, Technology, Electronic Commerce, Fintech, Digital Cash Management, Digital Assets, ACI Worldwide, Organization, GlobalData, GDP, Ecosystem, ACIW, Central Bank of Myanmar, ACI, Partnership, Central bank, Growth, Overalls, Government, Cryptocurrency, Economics

The Central Bank of Colombia, Banco de la República , today announced it is partnering with ACI Worldwide (NASDAQ: ACIW), the global leader in mission-critical, real-time payments software , to build a new domestic real-time payments ecosystem as part of a nationwide banking transformation project.

Key Points: 
  • The Central Bank of Colombia, Banco de la República , today announced it is partnering with ACI Worldwide (NASDAQ: ACIW), the global leader in mission-critical, real-time payments software , to build a new domestic real-time payments ecosystem as part of a nationwide banking transformation project.
  • All current and future schemes will need to connect to the new real-time payments ecosystem to be built.
  • “We are excited about the real-time payments modernization journey we have embarked upon jointly with ACI Worldwide, a global leader in real-time payments,” said Leonardo Villar, Governor of the Central Bank of Colombia.
  • Colombia like other countries in the region is primed to realize significant economic benefits for businesses and consumers from the adoption of real-time payments.

ACI Worldwide Scamscope Report Finds APP Scam Losses Expected To Hit $6.8 Billion by 2027

Retrieved on: 
Tuesday, December 5, 2023
Security, Data Management, Technology, Banking, Other Consumer, Professional Services, Women, Seniors, Men, Artificial Intelligence, Digital Cash Management, Digital Assets, Other Technology, Payments, Networks, Consumer, Mobile, Wireless, ACI Worldwide, Human, Pressure, Telephone, GlobalData, IP, Head, Competition, Fraud, Multimedia, APP, Accord, Trust, Intelligence, Machine learning, Euro Banking Association, Social media, Table, Growth, AI, Indian Banks' Association, Government, Cryptocurrency, Online shopping

Real-time payments leap ahead of APP scams, yet caution prevails

Key Points: 
  • Real-time payments leap ahead of APP scams, yet caution prevails
    APP scam losses in the U.S. are projected to increase by 9% from 2022 to 2027.
  • According to the Scamscope report, APP scam losses in the U.K. hit more than $587 million in 2022.
  • With APP scam losses expected to reach $1.5 billion by 2027, Australians have implored their government to follow the U.K.’s lead.
  • According to the Scamscope report, approximately 3 out of 10 fraud victims close their accounts, posing financial consequences for banks.

J.D. Power-GlobalData Forecast November 2023

Retrieved on: 
Wednesday, November 22, 2023
Alternative Vehicles, Fuels, Fleet Management, General Automotive, Automotive, EV, Electric Vehicles, Growth, SAAR, Increment, Health, Insurance, J.D. Power, MSRP, UAW, GlobalData, Retail

Total new-vehicle sales for November 2023, including retail and non-retail transactions, are projected to reach 1,236,000 units, a 10.2% increase from November 2022, according to a joint forecast from J.D.

Key Points: 
  • Total new-vehicle sales for November 2023, including retail and non-retail transactions, are projected to reach 1,236,000 units, a 10.2% increase from November 2022, according to a joint forecast from J.D.
  • November 2023 has 25 selling days, the same as November 2022.
  • New-vehicle retail sales for November 2023 are expected to increase when compared with November 2022.
  • Despite these gains, the November 2023 year-to-date sales volume remain below pre-pandemic levels when year-to-date sales exceeded 15.4 million units.

New OfferUp Study Reveals Resale Gifting is Gaining Momentum for the 2023 Holiday Season as Stigma Around Giving and Receiving Secondhand Gifts Decreases

Retrieved on: 
Thursday, November 30, 2023
Holiday, Research, GlobalData, Electronics, City, Face, Recession, Online shopping, Retail, OfferUp

This increase in acceptance coincides with an overall decline in stigma around secondhand gifting, with 67% of shoppers saying the stigma has lessened.

Key Points: 
  • This increase in acceptance coincides with an overall decline in stigma around secondhand gifting, with 67% of shoppers saying the stigma has lessened.
  • OfferUp also announces the most popular secondhand gifts across cities in the United States.
  • The 2023 OfferUp Recommerce Report: Holiday Special Release reveals that 75% of shoppers are open to giving secondhand holiday gifts in 2023, while 82% of shoppers are open to receiving secondhand holiday gifts, marking an 11% increase since 2022 and indicating more widespread societal acceptance ahead of the 2023 season.
  • 82% of shoppers are open to receiving secondhand holiday gifts in 2023—marking an 11% increase from 2022.

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

Retrieved on: 
Wednesday, November 29, 2023
Acquisition, Senior, GlobalData, Patient, FTD, Conference, ORR, Cancer, Pancreatic Cancer Action Network, Diagnosis, Oncology, Congress, TSX, Bristol Myers Squibb, Food, Progression-free survival, Oncolytics Biotech, ESMO, Lilly, ECIS, Afatinib, Cabozantinib, Data, Pancreatic cancer, Pelareorep, ONC, Exelixis, CAD, PFS, Drug resistance, Eli Lilly and Company, Gemcitabine, Glomus tumor, Safety, NYSE, Mirati Therapeutics, Disease, Clinical trial, Radiopharmaceutical, Death, FDA, Medical Affairs Bureau, LLY, News, Survival, Pharmaceutical industry

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ -- USA News Group  -  According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a trend that's happening in North America too, especially among young people. Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers. Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer. Among the top developers putting out promising results with new treatments are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eli Lilly and Company (NYSE:LLY), and POINT Biopharma Global Inc. (NASDAQ:PNT).

Key Points: 
  • Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers.
  • Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer.
  • Late last year, favourable data from trials involving pelareorep in treating pancreatic cancer led to the FDA rewarding it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • By mid-2023, the Pancreatic Cancer Action Network (PanCAN) selected pelareorep for their pivotal Phase 3 trial , called Precision Promise.

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

Retrieved on: 
Wednesday, November 29, 2023
Acquisition, Senior, GlobalData, Patient, FTD, Conference, ORR, Cancer, Pancreatic Cancer Action Network, Diagnosis, Oncology, Congress, TSX, Bristol Myers Squibb, Food, Progression-free survival, Oncolytics Biotech, ESMO, Lilly, ECIS, Afatinib, Cabozantinib, Data, Pancreatic cancer, Pelareorep, ONC, Exelixis, CAD, PFS, Drug resistance, Eli Lilly and Company, Gemcitabine, Glomus tumor, Safety, NYSE, Mirati Therapeutics, Disease, Clinical trial, Radiopharmaceutical, Death, FDA, Medical Affairs Bureau, LLY, News, Survival, Pharmaceutical industry

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ -- USA News Group  -  According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a trend that's happening in North America too, especially among young people. Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers. Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer. Among the top developers putting out promising results with new treatments are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eli Lilly and Company (NYSE:LLY), and POINT Biopharma Global Inc. (NASDAQ:PNT).

Key Points: 
  • Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers.
  • Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer.
  • Late last year, favourable data from trials involving pelareorep in treating pancreatic cancer led to the FDA rewarding it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • By mid-2023, the Pancreatic Cancer Action Network (PanCAN) selected pelareorep for their pivotal Phase 3 trial , called Precision Promise.